

FILED

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF VIRGINIA**

2016 SEP -2 P 12:11

ELI LILLY AND COMPANY and ICOS)
CORPORATION,)
)
Plaintiffs,)
)
v.)
)
MYLAN PHARMACEUTICALS INC.)
)
Defendant.)

CIVIL ACTION NO. 1:16 CV 1122-LO/TCB

COMPLAINT

Plaintiffs Eli Lilly and Company (“Lilly”) and ICOS Corporation (“ICOS”) (collectively “Plaintiffs”) file this Complaint for patent infringement against Mylan Pharmaceuticals Inc. (“Mylan” or “Defendant”) under 35 U.S.C. § 271(e)(2) for infringement of U.S. Patent No. 6,943,166 (“the ’166 patent”).

NATURE OF THE ACTION

1. This is an action for patent infringement arising under the patent laws of the United States, Title 35, United States Code, against Mylan. This action relates to Abbreviated New Drug Application No. 206956 (“tadalafil ANDA”) submitted by Mylan to the U.S. Food and Drug Administration (“FDA”) for approval to market a generic version of Lilly’s Cialis® (tadalafil) tablets (“proposed tadalafil ANDA product”) prior to the expiration of the ’166 patent. Mylan’s tadalafil ANDA includes a “Paragraph IV certification” asserting that the ’166 patent is invalid, unenforceable, and/or will not be infringed by the commercial manufacture, use, and sale of Mylan’s proposed tadalafil ANDA product, which constitutes an act of infringement under the United States Patent Laws, Title 35 U.S.C. § 100 *et seq.*, including 35 U.S.C. § 271(e)(2).

THE PARTIES

2. Lilly is an Indiana Corporation that has its corporate offices and principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285. Lilly is engaged in the business of research, development, manufacture, and sale of pharmaceutical products throughout the world.

3. ICOS is a Delaware corporation having its corporate office at Lilly Corporate Center, Indianapolis, Indiana 46825. ICOS is a wholly owned subsidiary of Lilly.

4. On information and belief, Mylan is a corporation organized and existing under the laws of the State of West Virginia, having a principal place of business at 781 Chestnut Ridge Rd, Morgantown, West Virginia, 26505.

5. On information and belief, Mylan is a pharmaceutical company that formulates, manufactures, packages, and markets generic drug products for distribution in the Eastern District of Virginia and throughout the United States.

6. On information and belief, as stated in its 2016 Annual Report, Mylan, together with its related corporate entities, “is one of the largest generic and specialty pharmaceuticals companies in the world in terms of revenue,” “holds the number two ranking in the U.S. generics prescription market both in terms of sales and prescriptions dispensed,” and supplies “[a]pproximately, one in every 13 prescriptions dispensed in the U.S....”

JURISDICTION AND VENUE

7. Each of the preceding paragraphs 1 to 6 is re-alleged and re-incorporated as if fully set forth herein.

8. This action arises under the patent laws of the United States, 35 U.S.C. §§ 100, et seq., and this Court has jurisdiction over the subject matter of this action under 28 U.S.C. §§ 1331, 1338(a), 2201, and 2202.

9. Venue is proper in this Court under 28 U.S.C. §§ 1391 and 1400(b).

10. Mylan is subject to personal jurisdiction in this District due, among other things, to its substantial, systematic, purposeful, and continuous contact in this District.

11. Mylan is registered to do business in the Commonwealth of Virginia and has a registered agent for service of process in this Judicial District.

12. Since at least 2010, Mylan has maintained an active license with the Virginia Department of Health Professions as a “Non-Resident Wholesale Distributor,” which permits Mylan to directly distribute prescription drugs to pharmacies, physicians, and other retail entities throughout the Commonwealth of Virginia. On information and belief, pursuant to its Non-Resident Wholesale Distributer license, Mylan distributes prescription drugs in this District.

13. Mylan is a pharmaceutical vendor for the Minnesota Multistate Contracting Alliance for Pharmacy (MMCAP) which sells pharmaceuticals in the Eastern District of Virginia and in a number of states. In 2015, 15% of Mylan’s net sales were to McKesson Corporation, and 12% of Mylan’s sales were to Cardinal Health, Inc.; both are nationwide distributors with facilities in the Eastern District of Virginia.

14. Mylan solicits customers in the Eastern District of Virginia using its extensive website. Through Mylan’s interactive website, customers and potential customers throughout the United States, including in the Eastern District of Virginia can, among other things: (1) search and download prescribing information for Mylan’s full product line; (2) request Mylan’s Generic Brand Reference Guide which catalogs brand name products with corresponding Mylan

generic products; (3) submit product return requests; and (4) download patient materials and health information.

15. Mylan consented to personal jurisdiction in the Eastern District of Virginia in another action. *GD Searle LLC v. Lupin Pharmaceuticals, Inc.*, 2:13-cv-00121 (E.D. Va. 2014).

16. Mylan has also previously availed itself of the benefits of the Eastern District of Virginia Courts by filing suit in this jurisdiction, including, at least, suing Lilly in this court. *Mylan Pharmaceuticals Inc. v. Eli Lilly*, 3:08-cv-144 (E.D. Va. 2008).

17. Mylan is also subject to specific jurisdiction in this District based on the filing of its tadalafil ANDA with a Paragraph IV certification regarding the '166 patent. *See Acorda Therapeutics Inc. v. Mylan Pharm. Inc.*, 817 F.3d 755 (Fed. Cir. 2016).

18. As in *Acorda*, “Mylan has taken the costly, significant step of applying to the FDA for approval to engage in future activities—including the marketing of its generic drugs—that will be purposefully directed at,” on information and belief, this District and elsewhere. *Acorda Therapeutics*, 817 F.3d at 759.

19. “Mylan's ANDA filings constitute formal acts that reliably indicate plans to engage in marketing of the proposed generic drugs.” *Acorda Therapeutics*, 817 F.3d at 760.

20. As in *Acorda*, on information and belief “Mylan intends to direct sales of its drugs into [Virginia], among other places, once it has the requested FDA approval to market them.” *Acorda Therapeutics*, 817 F.3d at 758.

21. On information and belief, Mylan will engage in marketing of its proposed tadalafil ANDA product in Virginia, including the Eastern District of Virginia, upon approval of its tadalafil ANDA.

22. Mylan's ANDA filing, including its Paragraph IV certifications regarding the '166 patent at issue here, is suit-related, and has a substantial connection with this District because it reliably, non-speculatively predicts activities in this District by Mylan.

23. "[T]he minimum-contacts standard is satisfied by the particular actions Mylan has already taken—its ANDA filing[]—for the purpose of engaging in that injury-causing and allegedly wrongful marketing conduct in" this District. *Acorda Therapeutics*, 817 F.3d at 760.

24. Exercising personal jurisdiction over Mylan in this District would not be unreasonable given Mylan's size, contacts in this District, and the interest in this District of resolving disputes related to products to be sold herein.

PATENT-IN-SUIT

25. On September 13, 2005, the U.S. Patent and Trademark Office duly and legally issued the '166 patent, entitled "Compositions Comprising Phosphodiesterase Inhibitors for the Treatment of Sexual Dysfunction." A true and correct copy of the '166 patent is attached hereto as Exhibit A. The claims of the '166 patent are valid and enforceable. At the time of its issue, the '166 patent was assigned to Lilly ICOS, LLC and it was subsequently assigned to ICOS which currently holds title.

26. Lilly is the holder of NDA No. 021368 by which FDA granted approval for the marketing and selling of tadalafil tablets in 2.5 mg, 5 mg, 10 mg, and 20 mg dosage strengths for the treatment of erectile dysfunction. Lilly markets tadalafil tablets in the United States under the name "Cialis[®]" in 2.5 mg, 5 mg, 10 mg, and 20 mg dosage strengths. The '166 patent is one of the patents listed in the FDA publication entitled Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book) as covering the approved indications for Cialis[®].

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.